Screener
Relmada Therapeutics, Inc. RLMD Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
| Unrealized (loss)/gain on short-term investments | (540,097) | 155,731 |
| Total other income, net | 409,798 | 658,970 |
| Net loss | $(19,051,956) | $(17,559,465) |
| Loss per common share – basic and diluted | $(0.22) | $(0.58) |
| Weighted average number of common shares outstanding – basic and diluted | 86,596,873 | 30,408,890 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s net income?
- Relmada Therapeutics, Inc. (RLMD) reported net income of -$19.05M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s net income changed year-over-year?
- Relmada Therapeutics, Inc.'s net income decreased by 8.5% year-over-year, from -$17.56M to -$19.05M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s net income has grown at a -17.8% compound annual growth rate (CAGR), from -$125.75M to -$57.39M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Relmada Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude